IL282842A - Pharmaceutical formulations for subcutaneous administration - Google Patents
Pharmaceutical formulations for subcutaneous administrationInfo
- Publication number
- IL282842A IL282842A IL282842A IL28284221A IL282842A IL 282842 A IL282842 A IL 282842A IL 282842 A IL282842 A IL 282842A IL 28284221 A IL28284221 A IL 28284221A IL 282842 A IL282842 A IL 282842A
- Authority
- IL
- Israel
- Prior art keywords
- medicinal compounds
- subcutaneous control
- subcutaneous
- control
- medicinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767546P | 2018-11-15 | 2018-11-15 | |
| US201962843945P | 2019-05-06 | 2019-05-06 | |
| US201962863101P | 2019-06-18 | 2019-06-18 | |
| US201962863113P | 2019-06-18 | 2019-06-18 | |
| US201962863093P | 2019-06-18 | 2019-06-18 | |
| US201962898214P | 2019-09-10 | 2019-09-10 | |
| PCT/US2019/061626 WO2020102628A1 (en) | 2018-11-15 | 2019-11-15 | Pharmaceutical formulations for subcutaneous administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL282842A true IL282842A (en) | 2021-06-30 |
Family
ID=68835352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL282842A IL282842A (en) | 2018-11-15 | 2021-05-02 | Pharmaceutical formulations for subcutaneous administration |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US12251365B2 (https=) |
| EP (1) | EP3880210A1 (https=) |
| JP (2) | JP2022507528A (https=) |
| KR (1) | KR20210091139A (https=) |
| CN (1) | CN113015531A (https=) |
| AU (2) | AU2019379806B2 (https=) |
| BR (1) | BR112021009353A2 (https=) |
| CA (1) | CA3117983A1 (https=) |
| IL (1) | IL282842A (https=) |
| MX (1) | MX2021005776A (https=) |
| SG (1) | SG11202104499RA (https=) |
| TW (1) | TW202031265A (https=) |
| UY (1) | UY38473A (https=) |
| WO (1) | WO2020102628A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021009353A2 (pt) | 2018-11-15 | 2021-11-23 | Abbvie Inc | Formulações farmacêuticas para administração subcutânea |
| WO2023049534A2 (en) | 2021-10-27 | 2023-03-30 | Abbvie Inc. | Subcutaneously administered treatments for advanced parkinson's disease |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3132171A (en) | 1962-06-18 | 1964-05-05 | Strong Cobb Arner Inc | 3, 4-diphosphatophenyl-alanine and process for making same |
| US3998799A (en) | 1973-11-02 | 1976-12-21 | Interx Research Corporation | Novel, transient pro-drug forms of l-dopa |
| US3939253A (en) | 1973-11-02 | 1976-02-17 | Interx Research Corporation | Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease |
| US3891696A (en) | 1973-11-02 | 1975-06-24 | Interx Research Corp | Novel, transient pro-drug forms of l-dopa |
| US4065566A (en) | 1975-04-17 | 1977-12-27 | Interx Research Corporation | N-Nicotinoyl-3,4-dinicotinoyloxy-L-phenylalanine and derivatives pharmaceutical compositions and methods containing same |
| US4035507A (en) | 1975-04-17 | 1977-07-12 | Interx Research Corporation | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease |
| US4163058A (en) | 1977-04-22 | 1979-07-31 | Interx Research Corporation | Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof |
| US4618484A (en) | 1983-03-30 | 1986-10-21 | Yale University | Composition and method for treatment of melanomas |
| US4508706A (en) | 1983-03-30 | 1985-04-02 | Yale University | Composition for increasing melanin in mammalian skin and hair |
| IT1213182B (it) | 1984-06-25 | 1989-12-14 | Simes | Derivati di composti a struttura catecolamminica. |
| IT1200427B (it) | 1985-03-22 | 1989-01-18 | Afros Spa | Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura |
| JPH02138A (ja) | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | Ｌ‐ドーパ誘導体 |
| IT1226727B (it) | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
| ES2070994T3 (es) | 1989-04-20 | 1995-06-16 | Zambon Spa | Profarmaco de dopamina. |
| GB9102812D0 (en) | 1991-02-11 | 1991-03-27 | Enzymatix Ltd | Compounds |
| IT1255471B (it) | 1992-07-30 | 1995-11-02 | Zambon Spa | Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US5874468A (en) * | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6576766B1 (en) | 1997-11-12 | 2003-06-10 | Ariad Pharmaceuticals, Inc. | Signal transduction inhibitors, compositions containing them |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| CA2490626A1 (en) | 2002-06-20 | 2003-12-31 | Nippon Suisan Kaisha, Ltd. | Prodrug, medicinal utilization thereof and process for producing the same |
| US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
| WO2004069146A2 (en) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| DE602004031134D1 (de) | 2003-08-29 | 2011-03-03 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| ES2360759T3 (es) | 2003-08-29 | 2011-06-08 | Centocor Ortho Biotech Inc. | Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa. |
| KR20060108692A (ko) | 2003-10-31 | 2006-10-18 | 알자 코포레이션 | 메트포르민의 개선된 흡수를 위한 조성물 및 제형 |
| PT1751087E (pt) | 2004-06-04 | 2012-09-10 | Xenoport Inc | Derivados de levodopa e as suas composições e utilizações |
| CA2571726C (en) | 2004-07-06 | 2013-05-21 | Abbott Laboratories | Prodrugs of hiv protease inhibitors |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| US7563821B2 (en) | 2005-12-05 | 2009-07-21 | Xenoport, Inc. | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| WO2007138086A1 (en) | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa |
| KR20090033871A (ko) | 2006-06-16 | 2009-04-06 | 솔베이 파마슈티칼스 비. 브이 | 비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제 |
| CA2673336A1 (en) | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| GB0713189D0 (en) | 2007-07-06 | 2007-08-15 | Proximagen Ltd | Amino acid derivatives |
| EP2252284B1 (en) * | 2008-02-06 | 2011-05-25 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| JP5757864B2 (ja) | 2008-05-20 | 2015-08-05 | ニューロジェシックス， インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| PL2432454T3 (pl) | 2009-05-19 | 2017-10-31 | Neuroderm Ltd | Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy |
| SG179135A1 (en) | 2009-09-14 | 2012-05-30 | Abbott Lab | Methods for treating psoriasis |
| WO2011056240A2 (en) | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| EA026419B1 (ru) | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
| WO2011109767A2 (en) | 2010-03-04 | 2011-09-09 | University Of Notre Dame Du Lac | Gelatinase inhibitors and prodrugs |
| EP2575884B1 (en) | 2010-06-03 | 2018-07-18 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
| PT2640358T (pt) | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
| CN103228618B (zh) | 2010-12-02 | 2016-02-17 | 小野药品工业株式会社 | 新化合物及其医药用途 |
| WO2012079072A2 (en) | 2010-12-10 | 2012-06-14 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| US8765189B2 (en) | 2011-05-13 | 2014-07-01 | Howmedica Osteonic Corp. | Organophosphorous and multivalent metal compound compositions and methods |
| AU2014229127B2 (en) | 2013-03-13 | 2018-04-05 | Neuroderm Ltd | Method for treatment of parkinson's disease |
| CN112521305B (zh) | 2013-03-15 | 2023-04-25 | 苏州泰飞尔医药有限公司 | 治疗帕金森疾病的新型高穿透力药物及其药物组合物 |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| DK3116475T3 (da) | 2014-03-13 | 2020-12-07 | Neuroderm Ltd | Dopa-decarboxylasehæmmersammensætninger |
| RU2021103000A (ru) | 2014-10-21 | 2021-03-01 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| US20240024338A1 (en) | 2016-04-20 | 2024-01-25 | Abbvie Inc. | Carbidopa and l-dopa prodrugs and methods of use |
| EP4295909A3 (en) | 2016-04-20 | 2024-07-17 | AbbVie Inc. | Carbidopa and l-dopa prodrugs and methods of use |
| BR112019001229B1 (pt) | 2016-07-22 | 2022-11-16 | Syngenta Participations Ag | Composto derivado de oxadiazol, composição agroquímica compreendendo o mesmo, método para controlar ou impedir infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto como fungicida |
| US20190224153A1 (en) | 2016-09-29 | 2019-07-25 | Berlirem Gmbh | L-dopa derivatives for the treatment of neurological diseases |
| WO2018154447A1 (en) | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| BR112021009353A2 (pt) | 2018-11-15 | 2021-11-23 | Abbvie Inc | Formulações farmacêuticas para administração subcutânea |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| WO2023049534A2 (en) | 2021-10-27 | 2023-03-30 | Abbvie Inc. | Subcutaneously administered treatments for advanced parkinson's disease |
-
2019
- 2019-11-15 BR BR112021009353A patent/BR112021009353A2/pt unknown
- 2019-11-15 US US16/684,874 patent/US12251365B2/en active Active
- 2019-11-15 JP JP2021526553A patent/JP2022507528A/ja active Pending
- 2019-11-15 WO PCT/US2019/061626 patent/WO2020102628A1/en not_active Ceased
- 2019-11-15 EP EP19817519.2A patent/EP3880210A1/en active Pending
- 2019-11-15 KR KR1020217013385A patent/KR20210091139A/ko not_active Ceased
- 2019-11-15 MX MX2021005776A patent/MX2021005776A/es unknown
- 2019-11-15 TW TW108141664A patent/TW202031265A/zh unknown
- 2019-11-15 CN CN201980074883.1A patent/CN113015531A/zh active Pending
- 2019-11-15 AU AU2019379806A patent/AU2019379806B2/en active Active
- 2019-11-15 CA CA3117983A patent/CA3117983A1/en active Pending
- 2019-11-15 UY UY0001038473A patent/UY38473A/es unknown
- 2019-11-15 SG SG11202104499RA patent/SG11202104499RA/en unknown
-
2021
- 2021-05-02 IL IL282842A patent/IL282842A/en unknown
-
2024
- 2024-08-22 JP JP2024140691A patent/JP2024174894A/ja active Pending
-
2025
- 2025-02-10 US US19/049,546 patent/US20250186382A1/en active Pending
- 2025-03-11 US US19/076,082 patent/US20250325507A1/en active Pending
- 2025-10-23 AU AU2025256148A patent/AU2025256148A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250186382A1 (en) | 2025-06-12 |
| US20250325507A1 (en) | 2025-10-23 |
| WO2020102628A1 (en) | 2020-05-22 |
| US20200155578A1 (en) | 2020-05-21 |
| EP3880210A1 (en) | 2021-09-22 |
| JP2024174894A (ja) | 2024-12-17 |
| UY38473A (es) | 2020-06-30 |
| US12251365B2 (en) | 2025-03-18 |
| KR20210091139A (ko) | 2021-07-21 |
| MX2021005776A (es) | 2021-07-02 |
| JP2022507528A (ja) | 2022-01-18 |
| BR112021009353A2 (pt) | 2021-11-23 |
| AU2019379806A1 (en) | 2021-05-27 |
| AU2019379806B2 (en) | 2025-08-14 |
| CA3117983A1 (en) | 2020-05-22 |
| SG11202104499RA (en) | 2021-05-28 |
| TW202031265A (zh) | 2020-09-01 |
| AU2025256148A1 (en) | 2025-11-13 |
| CN113015531A (zh) | 2021-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3883623C0 (en) | MEDICAL INJECTION SYSTEM | |
| PL3827381T3 (pl) | Kontrola wielu kubitów | |
| UA36728S (uk) | Пристрій для ін`єкцій | |
| EP3856292C0 (en) | SAFETY SYRINGE | |
| IL282330A (en) | Therapeutic compounds | |
| EP3735463A4 (en) | Cytotoxicity-inducing therapeutic agent | |
| IL262535A (en) | Control device for controlling the administration of propofol to a patient | |
| HUE071268T2 (hu) | Készítmény szabályozott petefészek-stimuláláshoz | |
| IL282440A (en) | Inspection apparatus | |
| PL3206672T3 (pl) | Preparaty o przedłużonym uwalnianiu środków znieczulających miejscowo | |
| EP3823532C0 (en) | CANNULA INSERTION SYSTEM | |
| EP3646127C0 (de) | Rollstuhl-sondersteuerung | |
| IL282343A (en) | Aqueous pharmaceutical formulations | |
| DK3728220T3 (da) | Farmaceutiske forbindelser | |
| EP3815635A4 (en) | CATHETER | |
| IL282842A (en) | Pharmaceutical formulations for subcutaneous administration | |
| EP3904108A4 (en) | CARTRIDGE | |
| DK3621042T3 (da) | Kontrolfremgangsmåde | |
| EP3599687C0 (en) | MODULAR CONTROL DEVICE | |
| MA52268A (fr) | Seringue à distribution contrôlée | |
| EP3638348A4 (en) | SAFETY SYRINGE | |
| EP3678718A4 (en) | INCREMENTAL SYRINGE | |
| EP3744380A4 (en) | Catheter | |
| DK3620208T3 (da) | Kanyle | |
| DK3359102T3 (da) | Medicinsk plaster |